recombinant human apolipoprotein A-I

Recombinant human apolipoprotein A-I (rhApoA-I) is a biotechnologically engineered form of the primary protein component of high-density lipoprotein (HDL). It is designed to mimic the biological activity of endogenous ApoA-I, primarily by facilitating reverse cholesterol transport (RCT). In this process, rhApoA-I acts as an acceptor for cellular cholesterol and phospholipids via interaction with the ATP-binding cassette transporter A1 (ABCA1), forming pre-beta HDL particles. These particles are subsequently converted into mature HDL by lecithin-cholesterol acyltransferase (LCAT), for which ApoA-I is an essential cofactor. The mobilized cholesterol is then transported to the liver for biliary excretion. Beyond lipid management, rhApoA-I exhibits anti-inflammatory, anti-thrombotic, and antioxidant properties. Clinical development has primarily focused on acute coronary syndrome (ACS) to rapidly stabilize atherosclerotic plaques, though recent investigations have expanded into orphan indications like LCAT deficiency and systemic conditions like sepsis and COVID-19.

Other names

rhApoA-IRecombinant human ApoA-IRecombinant human apolipoprotein A1